Kore Private Wealth LLC Has $503,000 Stake in Amgen Inc. (NASDAQ:AMGN)

Kore Private Wealth LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 6.3% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 2,064 shares of the medical research company’s stock after purchasing an additional 122 shares during the period. Kore Private Wealth LLC’s holdings in Amgen were worth $503,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Kensington Investment Counsel LLC boosted its stake in shares of Amgen by 3.9% during the 2nd quarter. Kensington Investment Counsel LLC now owns 7,972 shares of the medical research company’s stock valued at $1,943,000 after buying an additional 301 shares during the period. Inscription Capital LLC boosted its stake in shares of Amgen by 809.1% during the 2nd quarter. Inscription Capital LLC now owns 68,976 shares of the medical research company’s stock valued at $16,813,000 after buying an additional 61,389 shares during the period. Tekla Capital Management LLC boosted its stake in shares of Amgen by 11.2% during the 2nd quarter. Tekla Capital Management LLC now owns 463,405 shares of the medical research company’s stock valued at $112,955,000 after buying an additional 46,845 shares during the period. Alpha Paradigm Partners LLC acquired a new stake in shares of Amgen during the 2nd quarter valued at $58,000. Finally, Proquility Private Wealth Partners LLC boosted its stake in shares of Amgen by 1.8% during the 2nd quarter. Proquility Private Wealth Partners LLC now owns 3,442 shares of the medical research company’s stock valued at $839,000 after buying an additional 62 shares during the period. 74.73% of the stock is owned by hedge funds and other institutional investors.

Shares of AMGN opened at $203.61 on Thursday. The company’s fifty day moving average price is $219.46 and its 200 day moving average price is $236.52. Amgen Inc. has a one year low of $200.47 and a one year high of $276.69. The company has a debt-to-equity ratio of 3.45, a current ratio of 1.31 and a quick ratio of 1.03. The company has a market capitalization of $115.62 billion, a PE ratio of 20.71, a price-to-earnings-growth ratio of 1.55 and a beta of 0.68.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Monday, August 2nd. The medical research company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.29. Amgen had a net margin of 22.55% and a return on equity of 99.85%. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $6.43 billion. Analysts anticipate that Amgen Inc. will post 16.41 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 8th. Stockholders of record on Tuesday, August 17th were issued a dividend of $1.76 per share. The ex-dividend date was Monday, August 16th. This represents a $7.04 annualized dividend and a dividend yield of 3.46%. Amgen’s payout ratio is 42.41%.

A number of brokerages have issued reports on AMGN. Robert W. Baird reissued a “sell” rating on shares of Amgen in a research note on Thursday, August 5th. William Blair reissued a “hold” rating on shares of Amgen in a research note on Friday, September 17th. Zacks Investment Research raised shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 price objective for the company in a research note on Tuesday, June 29th. Morgan Stanley reduced their price objective on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Daiwa Capital Markets lowered shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective for the company. in a research note on Thursday, September 23rd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $244.58.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Further Reading: Day Trading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.